NASDAQ · Financial Statements

IDEAYA Biosciences, Inc. (IDYA) Financial Statements

$34.71 NASDAQ: IDYA Market Cap $3.35B

IDEAYA Biosciences, Inc. most recently reported annual revenue of $219.0M, a net loss of $114.0M. Revenue grew at an average annual rate of 61.4% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

IDEAYA Biosciences, Inc.: net profit was positive in 0 of 9 reported years; operating margin moved from -180.9% to -72.8%, a shift of +108.1 percentage points; the most recent year shows a net loss of $114.0M.

Income Statement — 9 Years (USD millions)

Metric201720182019202020212022202320242025
Revenue$0$0$0$20.0M$28.0M$51.0M$23.0M$7.0M$219.0M
Operating Expenses$14.0M$36.0M$44.0M$55.0M$78.0M$113.0M$158.0M$334.0M$378.0M
Operating Profit$-14.0M$-36.0M$-44.0M$-35.0M$-50.0M$-63.0M$-134.0M$-327.0M$-159.0M
Operating Margin0.0%0.0%0.0%-180.9%-179.9%-122.7%-574.9%-4671.1%-72.8%
Other Income$3.0M$2.0M$2.0M$1.0M$1.0M$4.0M$21.0M$52.0M$46.0M
Interest$0$0$0$0$0$0$0$0$0
Depreciation$0$1.0M$1.0M$1.0M$2.0M$2.0M$4.0M$4.0M$5.0M
Profit Before Tax$-12.0M$-34.0M$-42.0M$-34.0M$-50.0M$-59.0M$-113.0M$-274.0M$-114.0M
Tax$0$0$0$0$0$0$0$0$0
Net Profit$-12.0M$-34.0M$-42.0M$-34.0M$-50.0M$-59.0M$-113.0M$-274.0M$-114.0M
EPS$-0.83$-2.41$-1.90$-1.31$-1.41$-1.42$-1.96$-3.36$-1.28
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$8.0M$4.0M$0$0$0$7.0M$0$0$208.0M$11.0M$7.0M$9.0M
Operating Expenses$42.0M$46.0M$51.0M$65.0M$67.0M$151.0M$84.0M$89.0M$99.0M$105.0M$115.0M$131.0M
Operating Profit$-34.0M$-42.0M$-51.0M$-65.0M$-67.0M$-144.0M$-84.0M$-89.0M$108.0M$-95.0M$-109.0M$-122.0M
Operating Margin-417.1%-1068.5%0.0%0.0%0.0%-2059.1%0.0%0.0%52.2%-869.5%-1654.6%-1380.7%
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$-27.0M$-34.0M$-40.0M$-53.0M$-52.0M$-130.0M$-72.0M$-77.0M$119.0M$-83.0M$-99.0M$-112.0M
Tax$0$0$0$0$0$0$0$0$0$0$0$0
Net Profit$-27.0M$-34.0M$-40.0M$-53.0M$-52.0M$-130.0M$-72.0M$-77.0M$119.0M$-83.0M$-99.0M$-112.0M
EPS$-0.46$-0.52$-0.53$-0.68$-0.60$-1.49$-0.82$-0.88$1.33$-0.94$-1.11$-1.22

Over the 9 years reported for IDEAYA Biosciences, Inc., borrowings increased from $3.0M in 2017 to $28.0M in 2025, cash stood at $113.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 11.31 times.

Balance Sheet — 9 Years (USD millions)

Metric201720182019202020212022202320242025
Total Assets$17.0M$97.0M$113.0M$298.0M$381.0M$388.0M$649.0M$1.1B$1.1B
Current Assets$14.0M$91.0M$102.0M$289.0M$251.0M$370.0M$533.0M$690.0M$667.0M
Cash$6.0M$21.0M$34.0M$72.0M$92.0M$69.0M$157.0M$84.0M$113.0M
Inventory$0$0$0$0$0$0$0$0$0
Receivables$0$0$0$2.0M$1.0M$0$0$0$6.0M
Fixed Assets$4.0M$5.0M$10.0M$9.0M$9.0M$9.0M$8.0M$28.0M$31.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0
Investments$7.0M$69.0M$66.0M$212.0M$276.0M$305.0M$476.0M$998.0M$937.0M
Other Assets$0$0$0$0$0$0$0$0$0
Total Liabilities$33.0M$145.0M$13.0M$100.0M$80.0M$39.0M$28.0M$65.0M$86.0M
Current Liabilities$2.0M$5.0M$7.0M$39.0M$45.0M$32.0M$27.0M$46.0M$59.0M
Borrowings$3.0M$0$7.0M$7.0M$5.0M$3.0M$3.0M$19.0M$28.0M
Other Liabilities$30.0M$145.0M$6.0M$93.0M$75.0M$35.0M$25.0M$46.0M$58.0M
Equity$0$0$0$0$0$0$0$0$0
Reserves$-16.0M$-49.0M$100.0M$198.0M$302.0M$349.0M$621.0M$1.1B$1.0B

For IDEAYA Biosciences, Inc., operating cash flow was positive in 1 of 9 reported years; free cash flow in the latest year was negative at $73.0M; free cash flow was positive in 1 of 9 years.

Cash Flow Statement — 9 Years (USD millions)

Metric201720182019202020212022202320242025
Operating Cash Flow$-12.0M$-28.0M$-39.0M$55.0M$-56.0M$-87.0M$-115.0M$-248.0M$-71.0M
Investing Cash Flow$-11.0M$-65.0M$1.0M$-147.0M$-72.0M$-37.0M$-161.0M$-506.0M$68.0M
Financing Cash Flow$0$0$0$2.0M$2.0M$2.0M$11.0M$14.0M$0
Net Cash Flow$-4.0M$15.0M$14.0M$38.0M$20.0M$-23.0M$89.0M$-73.0M$28.0M
Free Cash Flow$-14.0M$-29.0M$-41.0M$55.0M$-58.0M$-91.0M$-118.0M$-251.0M$-73.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.99
EV / EBITDA-15.57
FCF Yield-3.21%
Quick Ratio10.45
Interest Coverage—
Return 1Y60.89%
Return 3Y40.98%
Return 5Y82.24%

IDEAYA Biosciences, Inc. (IDYA) financials — frequently asked questions

What is IDEAYA Biosciences, Inc.'s annual revenue?

IDEAYA Biosciences, Inc. (IDYA) reported annual revenue of $219.0M in its most recent fiscal year.

What is IDEAYA Biosciences, Inc.'s net profit?

IDEAYA Biosciences, Inc. (IDYA) reported a net loss of $114.0M in its most recent fiscal year.

What is IDYA EV/EBITDA?

IDEAYA Biosciences, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -15.57. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
IDYA Overview IDYA Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.